LncRNAs and IgA nephropathy: underlying molecular pathways and clinical applications.

IF 3.2 4区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Clinical and Experimental Medicine Pub Date : 2025-05-06 DOI:10.1007/s10238-025-01660-9

Mina Alimohammadi, Samaneh Kahkesh, Amirhosein Abbasi, Mehrdad Hashemi, Seyedeh Mahdieh Khoshnazar, Afshin Taheriazam, Kiavash Hushmandi

{"title":"LncRNAs and IgA nephropathy: underlying molecular pathways and clinical applications.","authors":"Mina Alimohammadi, Samaneh Kahkesh, Amirhosein Abbasi, Mehrdad Hashemi, Seyedeh Mahdieh Khoshnazar, Afshin Taheriazam, Kiavash Hushmandi","doi":"10.1007/s10238-025-01660-9","DOIUrl":null,"url":null,"abstract":"<p><p>IgA nephropathy (IgAN), also known as Berger's disease, is a prevalent kidney disorder caused by the accumulation of IgA antibodies in the glomerular tissue. Long noncoding RNAs (lncRNAs), a class of noncoding RNAs longer than 200 nucleotides, play crucial roles in regulating various cellular and molecular processes, including translation, chromatin remodeling, and transcriptional efficiency. Research has highlighted the significant impact of lncRNA imbalances on the development and progression of kidney diseases, including IgAN. These molecules influence several key signaling pathways, such as PI3K/AKT/mTOR, PTEN, Notch, JNK, and immune-related pathways, with their dysregulation contributing to IgAN pathogenesis. This review aims to provide a comprehensive analysis of the molecular signaling pathways involving lncRNAs in IgAN, underscoring their potential as biomarkers for screening, diagnosis, and prevention. Furthermore, it explores the therapeutic potential of lncRNAs as precise targets for personalized treatment strategies.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"140"},"PeriodicalIF":3.2000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055897/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10238-025-01660-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

IgA nephropathy (IgAN), also known as Berger's disease, is a prevalent kidney disorder caused by the accumulation of IgA antibodies in the glomerular tissue. Long noncoding RNAs (lncRNAs), a class of noncoding RNAs longer than 200 nucleotides, play crucial roles in regulating various cellular and molecular processes, including translation, chromatin remodeling, and transcriptional efficiency. Research has highlighted the significant impact of lncRNA imbalances on the development and progression of kidney diseases, including IgAN. These molecules influence several key signaling pathways, such as PI3K/AKT/mTOR, PTEN, Notch, JNK, and immune-related pathways, with their dysregulation contributing to IgAN pathogenesis. This review aims to provide a comprehensive analysis of the molecular signaling pathways involving lncRNAs in IgAN, underscoring their potential as biomarkers for screening, diagnosis, and prevention. Furthermore, it explores the therapeutic potential of lncRNAs as precise targets for personalized treatment strategies.

查看原文本刊更多论文

lncrna和IgA肾病：潜在的分子途径和临床应用。

IgA肾病（IgAN），又称伯杰氏病，是一种常见的肾脏疾病，由肾小球组织中IgA抗体的积累引起。长链非编码rna （Long noncoding rna, lncRNAs）是一类长度超过200个核苷酸的非编码rna，在调节多种细胞和分子过程中起着至关重要的作用，包括翻译、染色质重塑和转录效率。研究强调了lncRNA失衡对包括IgAN在内的肾脏疾病的发生和进展的重要影响。这些分子影响几个关键的信号通路，如PI3K/AKT/mTOR、PTEN、Notch、JNK和免疫相关通路，它们的失调有助于IgAN的发病机制。本综述旨在提供IgAN中涉及lncrna的分子信号通路的全面分析，强调它们作为筛查、诊断和预防的生物标志物的潜力。此外，它还探索了lncrna作为个性化治疗策略的精确靶点的治疗潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Experimental Medicine 医学-医学：研究与实验

CiteScore

4.80

自引率

2.20%

发文量

159

审稿时长

2.5 months

期刊介绍： Clinical and Experimental Medicine (CEM) is a multidisciplinary journal that aims to be a forum of scientific excellence and information exchange in relation to the basic and clinical features of the following fields: hematology, onco-hematology, oncology, virology, immunology, and rheumatology. The journal publishes reviews and editorials, experimental and preclinical studies, translational research, prospectively designed clinical trials, and epidemiological studies. Papers containing new clinical or experimental data that are likely to contribute to changes in clinical practice or the way in which a disease is thought about will be given priority due to their immediate importance. Case reports will be accepted on an exceptional basis only, and their submission is discouraged. The major criteria for publication are clarity, scientific soundness, and advances in knowledge. In compliance with the overwhelmingly prevailing request by the international scientific community, and with respect for eco-compatibility issues, CEM is now published exclusively online.